Morgan Stanley Maintains Overweight on Eli Lilly, Lowers Price Target to $440
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and lowers the price target from $446 to $440.
This Is What Whales Are Betting On Eli Lilly
A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:LLY) we detected 12 strange trades.
On December 8, 2022, Z33 Bio Inc. An Entity Controlled By Zura Entered Into The License, Development And Commercialization Agreement With Eli Lilly And Company
As previously announced on June 16, 2022, JATT Acquisition Corp, a Cayman Islands exempted company (“JATT” or the “SPAC”) entered into a Business Combination Agreement (as it may be amended,
Lilly Announces 15% Dividend Increase, From $0.98 To $1.13 Per Share For Q1 2023 Dividend
The board of directors of Eli Lilly and Company (NYSE:LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2023 of $1.13 per share on
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Wells Fargo Maintains Equal-Weight on Eli Lilly, Raises Price Target to $375
Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Equal-Weight and raises the price target from $365 to $375.
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $5,800 Today
Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 1.57% on an annualized basis…
Eli Lilly’s Diabetes Drug Shows Statistical Reduction In Blood Sugar Levels In Children, Adolescents
Eli Lilly And Co’s (NYSE:LLY) DINAMO Phase 3 trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c…
Looking At Eli Lilly’s Recent Unusual Options Activity
Someone with a lot of money to spend has taken a bullish stance on Eli Lilly (NYSE:LLY).
And retail traders should know.
We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $401
Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $399 to $401.